BMRN Scraps BMN 401 After ENPP1 Trial Miss: $270M Lost

BioMarin Pharmaceutical (BMRN) officially ended development of BMN 401 across all indications on August 6, writing off the $270 million Inozyme Pharma acquisition completed in July 2025. The decision, disclosed alongside Q2 2026 earnings, comes three months after the Phase 3 ENERGY 3 trial missed one of two co-primary endpoints in ENPP1 deficiency.

BMN 401, a subcutaneous enzyme replacement therapy formerly called INZ-701, was tested in 27 children with ENPP1 deficiency, a rare genetic disorder that causes pathologic mineralization, including arterial calcification and a form of rickets. The trial met the biomarker endpoint: BMN 401 increased plasma inorganic pyrophosphate (PPi) levels through Week 52 versus conventional therapy. BioMarin called the increase statistically significant but did not disclose the magnitude or p-value. It missed the clinical endpoint of skeletal healing measured by X-ray. BioMarin acknowledged “no positive trends were observed” across secondary endpoints including rickets severity scores, body growth, and weight gain.

The Inozyme acquisition was the first major deal under Chief Business Officer James Sabry, the ex-Roche dealmaker hired in 2024. BMN 401 represented “substantially all” of the acquired asset value, meaning the entire $270 million purchase price evaporated in under 13 months. Guggenheim analysts had already pulled BMN 401 from their model in June, writing that “success is highly unlikely in light of these data.”

The write-off further narrows BioMarin’s pipeline, which has shed programs including its preclinical PKU gene therapy and now the entire ENPP1/ABCC6 deficiency platform. What cushions the blow is VOXZOGO. The achondroplasia drug generated $253 million in Q2 revenue, up 14% year over year, and management raised full-year 2026 guidance to at least $1 billion. The $4.8 billion Amicus Therapeutics acquisition added GALAFOLD and POMBILITI to the commercial rare disease stable.

But the risk is concentration. With BMN 401 written off and the PKU gene therapy program shelved, VOXZOGO is now the pipeline’s growth engine. The Amicus deal added GALAFOLD and POMBILITI, but both are mature products, not growth drivers. If the hypochondroplasia sNDA or the under-5 achondroplasia sNDA encounters regulatory friction, BioMarin’s growth narrative narrows to a single drug.

BMRN shares closed at $61.46 on August 6, market cap $11.9 billion. The stock absorbed the write-off because the bad news was telegraphed: the ENERGY 3 miss in May made discontinuation a matter of when, not if. Investors have since focused on VOXZOGO’s growth, including an sNDA for hypochondroplasia and a pending sNDA for children under 5 with achondroplasia.

What to watch: capital allocation. Management signaled it can “redeploy growth capital towards pipeline augmentation” within 12 to 18 months once the organic growth story is established. After the $270M Inozyme write-off and a second-quarter net income drop in part attributable to the impairment, investors will scrutinize whether the next M&A bet is on validated Phase 3 assets or earlier-stage programs with real biology behind them.

What It Means for the Trade

The stock absorbing the write-off without damage is the market correctly pricing pre-known information: Guggenheim had already stripped BMN 401 from models in June, and the ENERGY 3 miss in May made the discontinuation a scheduling question. What the write-off actually did was remove ambiguity from the BioMarin model — the question “does the ENPP1 program have salvage value?” is now answered at zero, and the company’s value equation is cleaner, if narrower. That narrowing is the real trading content: BioMarin is now, more explicitly than ever, a Voxzogo story with commercial-product ballast from the Amicus assets.

The $270 million lesson is in the deal post-mortem. Inozyme was the first major deal under CBO James Sabry, acquired for “substantially all” its value in BMN 401 — a subcutaneous enzyme replacement whose Phase 3 hit the biomarker (plasma PPi elevation through Week 52) and missed everything clinical (skeletal healing by X-ray, with “no positive trends” across rickets severity, growth, or weight gain). That is the specific, dangerous pattern of a therapy that engages the biology but doesn’t translate it into patient benefit — and the $270 million evaporated in 13 months. The market will apply this template to BioMarin’s next acquisition, which is why the Alesta HPP deal’s milestone-heavy, modest-upfront structure reads as learned behavior.

Pipeline and Franchise Context

The concentration math deserves sober treatment. Voxzogo at $253 million quarterly, growing 14%, with 2026 guidance raised to at least $1 billion — that is a genuine franchise, and the label-expansion runway (hypochondroplasia, under-5 achondroplasia) extends it. GALAFOLD and POMBILI from Amicus are cash-flow contributors in Fabry and Pompe, but mature: they defend the revenue base without changing the growth curve. The result is a company whose equity story has a single growth engine, and the engine’s durability is being tested in real time by BridgeBio’s oral infigratinib challenge in achondroplasia. Each Voxzogo regulatory event — the hypochondroplasia sNDA, the under-5 sNDA — is now a bigger share of the total thesis than it would be at a diversified pipeline company.

The ENPP1/ABCC6 platform exit also removes what was supposed to be the mineralization-disease adjacency: BioMarin had pitched calcification disorders as a natural extension of the skeletal franchise. That thematic option is gone, which sharpens the strategic dependence on skeletal dysplasia where the oral-versus-injectable fight with BridgeBio will decide franchise economics for a decade.

Risks and What Could Go Wrong

1. Voxzogo label-expansion friction: an sNDA delay or CRL in hypochondroplasia or under-5 achondroplasia removes the near-term growth legs and exposes the single-engine concentration at exactly the wrong moment.
2. Infigratinib’s approval converts achondroplasia into a share fight — even a modest oral-capture rate at the new-diagnosis decision point compounds against Voxzogo’s growth rate.
3. M&A credibility: a third disappointment would move the market’s read of BioMarin from “disciplined bolt-ons” to “serial value destruction,” compressing the multiple on everything.
4. Amicus-asset erosion: GALAFOLD faces eventual competitive pressure in Fabry, and if the ballast products decline while Voxzogo’s expansion slows, the total-revenue story stalls.

Position read: BMRN is a quality franchise with a concentration problem and a management team that just demonstrated it can cut losses cleanly. Hold the core, watch the two Voxzogo sNDAs as the dated catalysts, and let the next acquisition structure tell you whether the Inozyme lesson stuck.

Source: BioMarin Q2 2026 financial results press release